Breast Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Breast Cancer is a ~$4.3B Part D market in peak maturity, dominated by CDK4/6 inhibitors and kinase inhibitors with limited near-term patent risk.
Key Trends
- CDK4/6 inhibitors (Ibrance, Verzenio, Kisqali) account for 83% of tracked spending—a consolidated standard-of-care class
- Emerging estrogen receptor antagonists and HER2-targeted therapies represent narrow niche growth opportunities
- Heavy trial activity (3,318 trials, 1,009 in Phase 2) signals continued pipeline investment, but market consolidation around existing winners
Career Verdict
Strong career choice for oncology specialists seeking established infrastructure, high salaries, and stable employment; less suitable for entrepreneurial roles or high-growth ambitions.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IBRANCE (palbociclib) | Pfizer | $2.0B | 47% | PEAK | Stable | 10.5yr |
| 2 | VERZENIO (abemaciclib) | Eli Lilly and Company | $757M | 18% | PEAK | Stable | 5.1yr |
| 3 | KISQALI (ribociclib) | Novartis | $371M | 9% | PEAK | Stable | 9.6yr |
| 4 | PIQRAY (alpelisib) | Novartis | $138M | 3% | PEAK | Stable | 6.6yr |
| 5 | ORSERDU (elacestrant) | Stemline Therapeutics | $128M | 3% | PEAK | Growing | 11.4yr |
Drug Class Breakdown
Consolidated standard-of-care; limited differentiation
Mature, overlap with above class
Niche growth, later-line positioning
Mature, subtype-specific
Declining relevance in modern regimens
Career Outlook
StableBreast cancer remains a cornerstone of oncology portfolios with predictable, high-revenue drugs and established care pathways. Market growth is incremental, driven by biomarker-refined patient segmentation, combination therapies, and emerging mechanisms rather than breakthrough single agents. Career advancement is strongest for professionals who combine oncology domain expertise with health economics, payer strategy, or biomarker/companion diagnostics literacy.
Breaking In
Enter via Commercial or Medical Affairs tracks; a strong foundation in oncology fundamentals (HER2/ER status, standard-of-care sequencing, CDK4/6 rationale) and payer/HCP communication will differentiate you in a crowded field.
For Experienced Professionals
If you have 5+ years in breast cancer or oncology, pivot toward health economics, biomarker commercialization, or pipeline/late-stage project leadership to command $300K+ roles; staying in field-based commercial roles alone will plateau faster as the market matures.
In-Demand Skills
Best For
Hiring Landscape
Breast cancer hiring is concentrated in Commercial (1,666 roles, $255K avg) and Medical Affairs (264 roles, $302K avg), reflecting mature market focus on market access, key opinion leader engagement, and payer negotiations. R&D hiring (331 roles, $222K avg) is steady but not accelerating; manufacturing roles (395, $152K) support stable generic/biosimilar competition. Top hiring companies include AstraZeneca (1,373 roles across portfolio, not breast cancer–specific), indicating that breast cancer specialists are absorbed into larger oncology teams.
Top Hiring Companies
By Department
Solid employment stability and above-average compensation for commercial and medical affairs roles; R&D and clinical roles offer intellectual challenge but narrower entry gates.
On Market (27)
Approved therapies currently available
Competitive Landscape
241 companies ranked by most advanced pipeline stage
+211 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 48 trials with date data
Clinical Trials (50)
Total enrollment: 7,800 patients across 50 trials
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)
Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane
Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Residual Curarization and Its Incidence at Tracheal Extubation (P08194)
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
A Multi-centric Study to Assess the Efficacy of Sigmart in Subjects With Recurrent Angina After Coronary Revascularization
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
Rizatriptan 10 MG RPD in the Treatment of Acute Migraine
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis
Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer
Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis
Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers
Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
Liver Safety Under Upfront Arimidex vs Tamoxifen
Two Rizatriptan Prescribing Portions for Treatment of Migraine
Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
Influenza Vaccination in Immunocompromized Patients
Wellbutrin XL, Major Depressive Disorder and Breast Cancer
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Pamidronate Administration in Breast Cancer Patients With Bone Metastases
6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N+ Breast Cancer
Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Related Jobs in Oncology
Oncology Account Specialist Breast Franchise – Grand Rapids Territory
Oncology Account Specialist (Breast Cancer) - Winston Salem/Charlotte
Global Medical Affairs Leader, Breast
Senior Director of Trade and Channel Management
Senior Director of Trade and Channel Management
Senior Manager, GCP Quality Assurance
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.